Skip to main content

Exiqon's Q3 Revenues Increase 30 Percent

NEW YORK (GenomeWeb News) – Exiqon reported today that its third-quarter revenues jumped 30 percent year over year.

The Danish miRNA research products and diagnostics firm brought in total revenues of DKK 27.1 million ($5 million) for the quarter ended Sept. 30, compared to DKK 20.9 million for the third quarter of 2010. It said that its research product sales grew 33 percent year over year.

The firm said that for the last 10 consecutive quarters its product sales, excluding OEM sales and reagent sales associated with license agreements, increased 8 percent, on average, quarter over quarter.

Exiqon's net loss for the period was DKK 8.2 million, or DKK .22 per share, compared to a loss of DKK 13 million, or DKK .39 per share, for Q3 2010.

Its R&D expenses declined around 7 percent to DKK 5.7 million from DKK 6.1 million, while its sales, marketing, and administrative spending increased 46 percent to DKK 20.1 million from DKK 13.8 million.

Exiqon expects to report full-year 2011 revenues of DKK 110 million and EBITDA, excluding one-time litigation costs, of around DKK .00.

The Scan

Possibly as Transmissible

Officials in the UK say the B.1.617.2 variant of SARS-CoV-2 may be as transmitted as easily as the B.1.1.7 variant that was identified in the UK, New Scientist reports.

Gene Therapy for SCID 'Encouraging'

The Associated Press reports that a gene therapy appears to be effective in treating severe combined immunodeficiency syndrome.

To Watch the Variants

Scientists told US lawmakers that SARS-CoV-2 variants need to be better monitored, the New York Times reports.

Nature Papers Present Nautilus Genome, Tool to Analyze Single-Cell Data, More

In Nature this week: nautilus genome gives peek into its evolution, computational tool to analyze single-cell ATAC-seq data, and more.